Montelukast Denk

Montelukast, the active ingredient in Montelukast Denk, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Denk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. It offers reliable supply chain management, batch traceability, and responsive customer support to meet the needs of healthcare providers.

Montelukast acts on the leukotriene pathway to manage several respiratory conditions.

Asthma: improves control of chronic airway inflammation and reduces frequency of exacerbations. Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergic triggers. Exercise‑induced bronchoconstriction: prevents airway narrowing during or after physical activity.

Montelukast may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness - Fatigue

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema, or anaphylaxis - Mood changes including depression, anxiety, or suicidal thoughts - Elevated liver enzymes or hepatitis - Severe skin reactions like Stevens‑Johnson syndrome - Eosinophilic granulomatosis with polyangiitis - Unexplained fever or systemic hypersensitivity

Before prescribing Montelukast, clinicians should consider several precautionary measures to ensure patient safety.

Assess asthma control: ensure patient is on appropriate baseline therapy before adding montelukast. Monitor for neuropsychiatric events: watch for mood changes, depression, or suicidal ideation during treatment. Evaluate hepatic function: consider baseline liver enzymes in patients with liver disease or concomitant hepatotoxic drugs. Avoid use in patients with known hypersensitivity to montelukast or any excipients in the formulation. Store at room temperature: keep below 25°C, protect from moisture and light in original packaging.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations, lowering effectiveness. - Rifampin: enzyme induction can decrease drug levels and therapeutic response. - Ketoconazole: may increase exposure, raising risk of adverse effects. - Carbamazepine: can lower montelukast concentrations, compromising control. - St. John’s wort: may diminish drug effectiveness through metabolic induction.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Theophylline: possible additive bronchial effects; observe respiratory status. - Beta‑agonists: monitor for overlapping respiratory actions. - ACE inhibitors: watch for cough exacerbation when combined. - Antidepressants: observe for overlapping neuropsychiatric symptoms.